Hew Health Field Notes
Dispatch 20 November 2026 5 min read

Tirzepatide Plateau: Labs & Peptide Protocols

Most patients on tirzepatide see steady movement on the scale for the first four to six months. Then something shifts. The weekly drop slows to a trickle, or stops entirely, even though the injection schedule and appetite suppression feel unchanged. This is the plateau conversation we have most often in

Tirzepatide Plateau: Labs & Peptide Protocols
Field Notes · Vol. I 20.11.2026

Most patients on tirzepatide see steady movement on the scale for the first four to six months. Then something shifts. The weekly drop slows to a trickle, or stops entirely, even though the injection schedule and appetite suppression feel unchanged. This is the plateau conversation we have most often in our practice, and it almost never has a single cause.

Before we talk about adjustments, I want to be clear about what a plateau actually is. A true stall means no meaningful change in weight, body composition, or waist circumference over roughly four to six weeks at a stable dose, with consistent adherence. A slower rate of loss is not a plateau. Losing half a pound a week when you were losing two is still progress, and bodies do not shed fat on a linear schedule.

Why Tirzepatide Loses Momentum

Tirzepatide works on both GLP-1 and GIP receptors, which is why it tends to outperform earlier incretin medications. But the body adapts. Receptor sensitivity changes. Resting metabolic rate drops as lean mass shifts. Thyroid output can decline modestly in response to caloric restriction. Ghrelin rises. Cortisol patterns change under the stress of sustained deficit. Any one of these can mask the medication's effect.

When a patient tells me they have stalled, my first question is rarely about the dose. It is about sleep, strength training, protein intake, alcohol, and stress load over the prior six weeks. Roughly half the time, the answer is in that conversation and we never need to touch the prescription.

The Lab Panel I Order at a Plateau

When the lifestyle picture looks solid and the scale still refuses to move, labs tell us what the history cannot. Here is what I typically review:

  • Complete thyroid panel: TSH, free T4, free T3, and reverse T3. A suppressed free T3 with rising reverse T3 is a classic adaptive response to prolonged caloric restriction.
  • Fasting insulin and glucose, with HOMA-IR calculated: Tirzepatide improves insulin sensitivity, but underlying resistance can still blunt fat loss, particularly in patients who started with significant metabolic dysfunction.
  • HbA1c: Useful for trend, not just absolute value.
  • Comprehensive metabolic panel and liver enzymes: Fatty liver improvement often parallels fat loss, and worsening enzymes can signal other issues.
  • Sex hormones: Total and free testosterone, estradiol, SHBG, and in women, a cycle-timed progesterone when relevant. Low testosterone in men and perimenopausal shifts in women both affect body composition independent of the medication.
  • Cortisol: Morning serum cortisol, and sometimes a four-point salivary panel if the history suggests dysregulation.
  • Vitamin D, B12, ferritin, and magnesium: Deficiencies that develop under reduced food intake and affect energy, training capacity, and recovery.
  • Lipid panel and ApoB: Not directly about the plateau, but important context for anyone on long-term hormone optimization or metabolic therapy.
  • hs-CRP: Chronic inflammation blunts weight response in ways patients can feel but not describe.

A DEXA scan is worth considering here as well. Scales lie. I have had patients convinced they were failing who had actually lost four pounds of fat and gained two pounds of muscle over eight weeks, which is an excellent outcome that the bathroom scale punishes them for.

What We Adjust First

Dose titration is the obvious lever, and sometimes the right one. If a patient is on 7.5 mg and tolerating it well without appetite return, moving to 10 mg may restart progress. But I am cautious about chasing the dose upward every time the scale stalls. Side effects accumulate, and the highest dose is not always the most effective one for a given patient's physiology.

If labs show a thyroid or hormone issue, we address that directly. A woman in perimenopause whose free testosterone is undetectable and whose estradiol is swinging wildly is not going to respond well to a dose bump. She needs hormone optimization alongside her Weight Management protocol. A man with a total testosterone of 280 ng/dL is fighting physiology that no incretin can overcome alone.

Sleep gets more attention than patients expect. Under six hours a night for even two weeks measurably raises ghrelin and reduces leptin. We often order a home sleep study when the history fits, because untreated sleep apnea is one of the most common hidden causes of a stalled Weight Management program in patients over 40.

Where Peptide Protocols Enter the Conversation

Peptides are not a magic unlock, and I want to say that plainly. They are adjunctive tools that may support specific physiological goals when used thoughtfully alongside the primary medication and lifestyle work. Several come up in plateau conversations.

Growth Hormone Secretagogues

Tesamorelin and the CJC-1295 with ipamorelin combination are the two I discuss most. Tesamorelin has data specifically around visceral adipose tissue reduction. CJC/ipamorelin supports endogenous growth hormone pulses, which can help preserve lean mass during a prolonged deficit. Preservation of muscle during Weight Management matters enormously, because lean tissue is what keeps resting metabolic rate from collapsing.

BPC-157

Patients who have ramped up training to break a plateau often develop tendon and joint complaints. BPC-157 protocols come up in that context, around recovery and tissue repair, not as a Weight Management tool itself.

AOD-9604

A fragment of growth hormone studied for its effects on lipolysis without the glucose impact of full GH. Modest effects in isolation, more interesting as part of a layered protocol.

Which peptide, if any, makes sense depends entirely on what the labs and the patient's goals show. I do not prescribe peptides reflexively at a plateau. I prescribe them when there is a specific physiological rationale and the patient understands what we are trying to accomplish.

The Protocols We Do Not Reach For

Stacking three peptides on top of a GLP-1/GIP agonist because the scale has not moved in three weeks is not sound medicine. Neither is cycling off tirzepatide abruptly to "reset," which tends to produce rapid regain and metabolic frustration. A plateau is a signal to investigate, not to pile on.

I also want to note that peptide therapies in this category are not FDA-approved for weight management or longevity use, and any protocol should be reviewed and prescribed by a physician who knows your full history and current labs.

What a Plateau Visit Actually Looks Like

In our practice, a plateau visit runs about 45 minutes. We review the food log and training data, look at sleep metrics if the patient wears a tracker, draw the lab panel described above, and often schedule a DEXA. Then we meet again once results are back and build the next 90 days with specific, measurable targets. Sometimes that includes a dose change. Sometimes it includes a peptide protocol. Often it includes neither, and the answer is addressing a thyroid shift, a sleep problem, or a protein intake that quietly dropped to 60 grams a day.

The patients who do best on long-term tirzepatide are the ones who treat a plateau as information rather than failure. The medication is doing its job. Your job, and ours, is to understand what the body is telling us and respond to it accurately.

If your Weight Management progress has stalled and you want a clinician to review your labs, your protocol, and the physiology behind what you are seeing, reach out to our team to request a consultation.


Related from Hew Health